Table 1.
Characteristics of prostate cancer (CAP) cases metastatic to the head and neck
| Case # | Site of mets | Gleason score | Presentation of metastasis | Age at CAP | Survival (years) | Year at mets |
|---|---|---|---|---|---|---|
| 1 | Virchow | 9 | Swelling | 52 | 1 | 1 |
| 2 | Skull (diffuse) | 4+X | Pain in cranium | 54 | 5 | 5 |
| 3 | Temporal lobe | 7 | Incontinence LE weakness | 69 | 10 | 8 |
| 4 | Dura matter | 5 | Diplopia, blindness | 74 | 9a | 1 |
| 5 | Dura matter | 7 | Confusion | 56 | 10a | 7 |
| 6 | Virchow | 7 | Neck mass | 79 | 3 | 1 |
| 7 | Orbit skull base | 9 | Blindness | 85 | 3 | 2 |
| 8 | Temporal lobe | 8 | HA | 59 | 5 | 3 |
| 9 | Virchow | 8 | Neck mass | 80 | 15 | 14 |
| 10 | Virchow | 6 | Neck mass | 57 | 13 | 9 |
| 11 | Midbrain, cavernous sinus | NA | Right hand weakness | 75 | 4 | 3 |
| 12 | Brain (diffuse) | 7 | Disequilibrium | 62 | 9 | 1 |
| 13 | Virchow | 9 | Neck mass | 57 | 7 | 7 |
| 14 | Orbit frontal lobe | NA | Proptosis, ptosis redness | 70 | 7 | 6 |
| 15 | Brain (diffuse) | 7 | Confusion, seizure | 63 | 2 | 2 |
| 16 | Temporal lobe | 7 | Left side weakness | 52 | 5 | 4 |
| 17 | Parotid | 9 | VII cranial nerve palsy | 62 | 1 | 1 |
| 18 | Clivus | NA | XII cranial nerve palsy | 59 | 5 | 5 |
| 19 | Brain (diffuse) | NA | NA | 58 | 10 | 10 |
| 20 | Sphenoid | 7 | Left side hyperreflexia, anisocoria | 71 | 10 | 10 |
| 21 | Orbit dura matter | NA | Blindness and headache | 63 | 3 | 2 |
| 22 | Virchow | NA | Neck mass | 75 | 4 | 2 |
| 23 | Virchow | 8 | Neck mass | 59 | 2 | 1 |
| 24 | Skull (fronto temporal) | NA | Confusion | 75 | 4 | 4 |
| Case # | PSA * serum | Hormone response | Treatment |
|---|---|---|---|
| 1 | 5,500 | Ref [1] | Goserelin, bicalutamide |
| 2 | >1,000 | Ref | Goserelin, flutamide, TRFP |
| 3 | 4 | Treatment late in the course of disease | Fronto temporal craniotomy, XRT, goserelin/flutamide, TURP |
| 4 | 2,522 | Sen [2] | Luperolide, ketoconazole, XRT |
| 5 | 938 | Sen | Goserelin, bicalutimide, flutamide, ketoconazole, TURP |
| 6 | 279 | Sen | Goserelin, bicalutimide, |
| 7 | 126 | Sen | XRT, goserelin, flutamide |
| 8 | 13 | Ref | Prostatectomy, goserelin, flutamide, ketoconazole, estramustine, VP 16, XRT |
| 9 | 7,869 | Ref | Prostatectomy, bicalutamide, |
| 10 | 5.2 | Ref | Prostatectomy, goserelin, bicalutimide, docetaxel |
| 11 | NA | Ref | Hormonal TX, XRT, vinblastine, estramustine |
| 12 | 284 | Sen | Orchiectomy, hormonal TX, XRT |
| 13 | 14 | Ref | XRT, goserelin, bicalutimide, ketoconazole, flutamide |
| 14 | 1165 | Ref | XRT, leperamide, bicalutamide, vinblastine, estramustine |
| 15 | 51 | Ref | Goserelin, flutamide |
| 16 | >100 | Ref | Craniotomy, TURP, orchiectomy, chemotherapy |
| 17 | NA | Ref | XRT, estramustine |
| 18 | 66 | Ref | XRT, total prostatectomy, bilateral orchiectomy |
| 19 | 214 | NA | Luperamide |
| 20 | 46 | Ref | XRT, hormonal therapy |
| 21 | 13 | Ref | XRT, hormonal therapy |
| 22 | 4 | Ref | XRT, estramustin/taxotere carboplatin, |
| 23 | 9 | Ref | Goserelin, bicalutamide, XRT |
| 24 | NA | Ref | Luperamide, bicalutimide |